Virios Therapeutics (VIRI) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free VIRI Stock Alerts $0.46 +0.03 (+7.05%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVirios Therapeutics, Inc. (VIRI)finance.yahoo.com - April 14 at 7:23 PMVirios Therapeutics seeks global patent for antiviral comboinvesting.com - March 28 at 11:45 PMVirios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDglobenewswire.com - March 26 at 9:15 AMVirios Therapeutics announces salary cuts for employees and boardinvesting.com - February 29 at 5:35 PMVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Resultsmarkets.businessinsider.com - February 29 at 12:35 PMVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 29 at 9:15 AMVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestonesmarkets.businessinsider.com - February 28 at 11:24 AMVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestonesglobenewswire.com - February 28 at 9:15 AMVirios Therapeutics Llc (VIRI)investing.com - February 27 at 7:37 AMVirios Therapeutics (VIRI) Price Target Increased by 14.29% to 4.08msn.com - February 25 at 12:10 AMVirios Therapeutics Inc Ordinary Shares VIRImorningstar.com - February 9 at 12:13 AMVIRI: Moving IMC-2 into Phase 2 Program in Long COVIDfinance.yahoo.com - February 7 at 1:09 PMFibromyalgia Treatment Market revenue to cross USD 536 Million by 2033, says Research Nesterfinance.yahoo.com - February 6 at 3:37 PMVirios Therapeutics Stock (NASDAQ:VIRI) Dividends: History, Yield and Datesbenzinga.com - January 23 at 10:37 PMVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDfinanznachrichten.de - January 22 at 3:19 PMVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDfinance.yahoo.com - January 22 at 10:18 AMVirios Therapeutics Reports Receipt Of FDA's Feedback On Requirements For Advancing IMC-2markets.businessinsider.com - January 2 at 9:21 AMVirios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVIDfinance.yahoo.com - January 2 at 9:21 AMVirios Therapeutics Inc Ordinary Sharesmorningstar.com - December 7 at 10:47 PMVirios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 14 at 1:38 PMVIRI: Provides Overview of Phase 3 Program in Fibromyalgiafinance.yahoo.com - November 13 at 3:00 PMVirios Therapeutics GAAP EPS of -$0.06 beats by $0.04msn.com - November 13 at 10:00 AMVirios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 13 at 10:00 AMVirios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 13 at 10:00 AMSenti stock soars 175% on Chinese development deal for cancer drugmsn.com - November 6 at 6:12 PMVirios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023finance.yahoo.com - November 6 at 8:11 AMVirios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023finance.yahoo.com - October 12 at 8:02 AMVirios Therapeutics Announces Termination of At-The-Market Sales Agreementfinance.yahoo.com - September 18 at 10:11 AMVirios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023finance.yahoo.com - September 12 at 10:26 AMVIRI: Phase 3 Program in Fibromyalgia to Initiate in mid-2024…finance.yahoo.com - August 15 at 1:58 PMWhat In The World Is Going On With Virios Therapeutics (VIRI) Stock?benzinga.com - August 14 at 3:20 PMVirios Therapeutics Shares Rise 11% After Halt to At-The-Market Offering Salesmarketwatch.com - August 14 at 3:20 PMVirios Therapeutics Announces Halt to At-The-Market Offering Salesfinance.yahoo.com - August 14 at 10:04 AMVirios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcriptfinance.yahoo.com - August 12 at 10:42 AMVirios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 10 at 10:22 AMVirios Therapeutics's Earnings Outlookbenzinga.com - August 9 at 1:34 PMVirios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgiafinance.yahoo.com - August 9 at 8:33 AMVirios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023finance.yahoo.com - August 3 at 4:48 PMVirios Therapeutics (VIRI) Price Target Increased by 75.00% to 3.57msn.com - August 2 at 7:59 AMVIRI: Encouraging Results for IMC-2 in Long COVID…finance.yahoo.com - July 24 at 2:26 PMVirios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M Peoplefinance.yahoo.com - July 17 at 3:47 PMVirios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Studyfinance.yahoo.com - July 17 at 10:27 AMCCL, S and LL are among pre market gainersseekingalpha.com - June 12 at 4:08 PMVirios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirementfinance.yahoo.com - May 25 at 6:06 PMVIRI: Ready to Move IMC-1 Into Phase 3 Program…finance.yahoo.com - May 16 at 5:18 PMVirios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgiafinance.yahoo.com - May 15 at 8:38 AM10-Q: VIRIOS THERAPEUTICS, INC.marketwatch.com - May 12 at 7:09 PMH.C. Wainwright Reaffirms Their Hold Rating on Virios Therapeutics (VIRI)markets.businessinsider.com - May 12 at 9:08 AMRecap: Virios Therapeutics Q1 Earningsbenzinga.com - May 11 at 8:05 AMVirios Therapeutics Announces First Quarter 2023 Financial Resultsfinance.yahoo.com - May 11 at 8:05 AM Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). VIRI Media Mentions By Week VIRI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIRI News Sentiment▼0.000.37▲Average Medical News Sentiment VIRI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIRI Articles This Week▼01▲VIRI Articles Average Week Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cyclerion Therapeutics News Hepion Pharmaceuticals News Longeveron News TFF Pharmaceuticals News Molecular Templates News Adial Pharmaceuticals News Akari Therapeutics News ASLAN Pharmaceuticals News Biofrontera News Galera Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIRI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersI’m afraid WWIII is a very real possibility Porter & CompanyThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
